Cysteine-string protein (CSP) is an extensively palmitoylated DnaJ-family chaperone, which exerts an important neuroprotective function. Palmitoylation is required for the intracellular sorting and function of CSP, and thus it is important to understand how this essential modification of CSP is regulated. Recent work identified 23 putative palmitoyl transferases containing a conserved DHHC domain in mammalian cells, and here we show that palmitoylation of CSP is enhanced specifically by co-expression of the Golgi-localised palmitoyl transferases DHHC3, DHHC7, DHHC15 or DHHC17. Indeed, these DHHC proteins promote stable membrane attachment of CSP, which is otherwise cytosolic. An inverse correlation was identified between membrane affinity of unpalmitoylated CSP mutants and subsequent palmitoylation: mutants with an increased membrane affinity localise to the ER and are physically separated from the G o l g i -l o c a l i s e d D H H C p r o t e i n s . Palmitoylation of an ER-localised mutant could be rescued by brefeldin A (BFA) treatment, which promotes the mixing of ER and Golgi membranes. Interestingly though, the palmitoylated mutant remained at the ER following BFA washout, and did not traffic to more distal membrane compartments. We propose that CSP has a weak membrane affinity that allows the protein to locate its partner Golgi-localised DHHC proteins directly by membrane 'sampling'. Mutations that enhance membrane association prevent sampling and lead to accumulation of CSP on cellular membranes such as the ER. The coupling of CSP palmitoylation to Golgi membranes may thus be an important requirement for subsequent sorting. S-palmitoylation, the attachment of palmitate groups onto cysteine residues via thioester bonds, regulates the membrane interactions of many proteins (1) (2) (3) (4) . In addition to functioning as a simple membrane anchor, palmitoylation can also regulate protein sorting and the microlocalisation of proteins within membranes (5) (6) (7) (8) (9) . Despite several attempts to identify palmitoyl transferases over many years, it was only relatively recently that palmitoylating enzymes containing a conserved DHHC-CRD (cysteinerich domain) were first identified in yeast (10, 11) , where they mediate the majority of palmitoylation reactions (12) . Subsequent analyses in mammalian cells identified a family of 23 proteins containing this conserved DHHC-CR domain and several of these proteins have since been shown to have palmitoyl transferase activity (13) (14) (15) (16) . Sequence analyses of DHHC proteins predict that they are polytopic membrane proteins, with the DHHC region present on the cytosolic face of the membrane (17) . Indeed, the DHHC domain may form part of the enzyme active site (10, 11, (13) (14) (15) . The finding that DHHC proteins are integral membrane proteins implies that substrates must contain additional membrane targeting signals to mediate membrane association prior to palmitoylation. This sets palmitoylation apart from isoprenylation and myristoylation, which occur in the cytosol, and indeed these hydrophobic modifications often facilitate membrane association of proteins prior to palmitoylation (e.g. H-/N-Ras and Src family kinases). The primary membrane targeting information contained within many palmitoylated proteins is easily identifiable (myristoyl and isoprenyl attachment sites or transmembrane domains). However, the mechanisms employed by other palmitoylated proteins for initial membrane targeting are less well understood. Cysteine-string protein (CSP) is a secretory vesicle protein that has been proposed to function in regulated exocytosis pathways in a range of non-neuronal cells, and is also essential in the nervous system where it has an important neuroprotective function (18) (19) (20) (21) (22) . CSP is extensively palmitoylated on up to 14 cysteine residues present within a central cysteine-rich domain (23) . CSP lacks transmembrane sequences or isoprenyl/myristoyl consensus sequences, and we recently reported that the cysteine-rich domain of CSP 'doubles up' as both a membrane targeting sequence and a palmitoylation domain (24) . Indeed, the minimal membrane targeting sequence of CSP (amino acids 106-136; cysteine-string domain is 113-136) binds tightly to cell membranes in the absence of detectable palmitoylation (24) . The identification of residues 106-136 as the minimal membrane targeting sequence of CSP agrees well with in silico analysis suggesting that residues 108-130 have a propensity to move from the aqueous environment to the membrane interface without traversing the bilayer (25) . Although membrane-bound, the unpalmitoylated CSP(106-136) and CSP(1-136) truncation mutants are mis-sorted in PC12 cells and show extensive overlap with ER markers, suggesting that palmitoylation is essential for correct intracellular sorting of CSP (24) . Two recent elegant studies reported a loss of CSP palmitoylation in the nervous system of DHHC17 mutant Drosophila, resulting in defects in presynaptic neurotransmission (26, 27) . However, the enzymes that palmitoylate mammalian CSP have not been identified, and indeed it is formally possible that the effects of DHHC17 mutation in Drosophila on CSP palmitoylation are indirect. In addition, CSP has a widespread tissue distribution outside the nervous system of both mammals and Drosophila (28) (29) (30) , and it is not clear whether the same DHHC protein(s) palmitoylate CSP in every cell type. To shed light on the pathway of CSP palmitoylation in mammalian cells, we have undertaken a detailed analysis of the DHHC proteins that palmitoylate CSP, identifying a subset of Golgi enzymes that fulfil this function. Furthermore, we present data on the mechanisms that govern intracellular interactions of CSP with its partner DHHC proteins.
Experimental Procedures Plasmid constructs, antibodies and chemicals
Mouse DHHC1-DHHC23 clones in pEF-BOS-HA were as previously described (14) . Plasmids containing bovine CSP1 fused to an N-terminal GFP-tag (pEGFP-C2), CSP4CL and CSP136, CSP137, CSP138, CSP139 and CSP140 truncation mutants were as previously described (20, 24) . Note that as in our previous work (24) , the initiating methionine was removed from CSP in all N-terminally-tagged constructs. EGFP-SNAP25B was constructed by inserting rat SNAP25B (lacking the initiating N-terminal methionine) into pEGFP-C2. Site-directed mutagenesis was employed to introduce the DHHC-to-DHHS mutations into DHHC3 and DHHC7; the fidelity of all mutant constructs was confirmed by DNA sequencing. Anti-GFP monoclonal antibody (JL8) was purchased from Clontech (California). Anti-HA monoclonal antibody and Rhodamineconjugated anti-HA were from Roche (East Sussex, UK). Anti-giantin Alexa Fluor 488-conjugated antibody was supplied by Cambridge Bioscience (Cambridge, UK). Rabbit anticalreticulin polyclonal antibody was from Abcam (Cambridge, UK). Anti-ERGIC53 antibody was from Sigma (Poole, UK). Anti-HA Alexa Fluor 488-conjugated monoclonal antibody and all fluorescent secondary antibodies were purchased from Invitrogen (Paisley, UK). Proteoextract S-PEK subcellular fractionation kit was purchased from Merck (Nottingham, UK). Lipofectamine 2000 was from Invitrogen (Paisley, UK). Anti-GFP magnetic isolation kits were obtained from Miltenyi Biotech (Surrey, UK). Promix L-[ 35 S] cysteine/methionine cell labelling mix and Amplify reagent were from Amersham (Buckinghamshire, UK). [ 3 H] palmitic acid was purchased from Perkin Elmer (Bucks, UK). Brefeldin A, nocodazole and cycloheximide were from Sigma (Poole, UK) Cell culture and cell transfection PC12 cells were grown in RPMI1640 media with 10% horse serum, 5% fetal calf serum and penicillin/streptomycin. HEK293 cells were cultured in DMEM with 10% fetal calf serum and penicillin/streptomycin. All reagents used for maintenance of cells were purchased from Invitrogen (Paisley, UK). Cells were maintained in a humidified atmosphere containing 5% CO 2 . For all experiments, cells were plated onto 6-well or 24-well plates that had been precoated with poly-D-lysine. Cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions; the ratio of lipofectamine:DNA used was 2:1.
Effect of DHHC co-expression on membrane association and palmitoylation of CSP in HEK293 Cells
HEK293 cells on 24-well plates were transfected with EGFP-CSP (0.8 µg) in the presence of individual HA-DHHC clones, empty pEFBOS-HA vector, or mutant DHHCs in which the conserved DHHC motif was mutated to DHHS (1.6 µg). For the dose-dependency analysis of EGFP-CSP palmitoylation by DHHC3 ( Figure  1C ), 0.8 µg EGFP-CSP was transfected together with a total of 1.6 µg empty pEFBOS-HA and HA-DHHC3. The cells were either lysed directly in 200 µl SDS-dissociation buffer or fractionated into cytosol and membrane fractions (150 µl of each) using an SPEK subcellular proteome extract kit, ~20 hours post-transfection. We have previously validated the use of the SPEK kit for separation of cytosolic and membrane proteins (24) . Equal volumes of the recovered cytosol and membrane fractions were mixed with SDSdissociation buffer. All samples were heated to 100 °C for 2 min, separated by SDS-PAGE and examined by immunoblotting using anti-GFP monoclonal antibody (JL8) or anti-HA. In some experiments, an insoluble (I) fraction was also collected following isolation of cytosol and membrane fractions. For this, cell material remaining after isolation of cytosol and membrane fractions was solubilised in an equivalent volume of SDS-dissociation buffer. Cytosol and membrane bands were quantified (ImageJ) for each sample and expressed as a % of membrane association. For analysis of BFA effects on CSP membrane binding/palmitoylation in HEK293 cells, the cells were incubated for 4 hours in transfection mix, which was then removed and replaced with fresh media with or without 30 µg/ml BFA. After a further 4 hours, the cells were washed and fractionated into cytosol and membrane fractions and processed as described above. 
Analysis of CSP Palmitoylation

Statistical Analysis
All averaged data are expressed as means +/-standard errors of the mean (SEM). Data was analysed using unpaired Student's t-test.
Results and Discussion
CSP Palmitoylation is Inefficient in HEK293 Cells and is Enhanced by Co-Expression of Specific Golgi-Localised DHHC Proteins
As previously shown (24) , when EGFP-CSP is expressed in PC12 cells, two bands are specifically detected by immunoblotting ( Figure  1A ). The lower molecular weight band (indicated by an a r r o w h e a d ) represents unpalmitoylated CSP and does not incorporate 3 H palmitate, whereas the upper band is fully palmitoylated and strongly incorporates radiolabel ( Figure 1A ) (24) . This change in migration that occurs following the extensive palmitoylation of CSP is well documented (23) (24) (25) (31) (32) (33) (34) . Indeed, the upper band migrates at the same size as the lower band following chemical depalmitoylation of CSP (see for example (24)). Employing this band-shift to measure CSP palmitoylation is a very useful approach, not least because it provides an accurate and quantitative assessment of the proportion of CSP molecules that are palmitoylated. In addition, as partially palmitoylated CSP molecules can be distinguished from fully palmitoylated protein by migration on polyacrylamide gels (24) , this analysis provides data on the extent of palmitoylation of individual molecules. Similar approaches employing [ 3 H] palmitate labelling do not allow a direct analysis of either the proportion of molecules that are palmitoylated or the level of palmitoylation of individual molecules. Whereas the upper palmitoylated band is the major form of EGFP-CSP in transfected PC12 cells, only a small pool of the protein is palmitoylated when expressed in HEK293 cells ( Figure 1A ). This suggests that only a limited amount of palmitoyl transferases active against CSP are expressed in HEK293 cells, and thus, we employed this cell type to characterise the palmitoylation of CSP in mammalian cells. Recent work identified a family of 23 putative mammalian palmitoylating enzymes containing a conserved DHHC motif (14) . Although several of these DHHC proteins have been shown to have palmitoyl transferase activity, at present a complete screen of all DHHC proteins for such activity is lacking. We co-transfected HEK293 cells with EGFP-CSP and HA-tagged versions of each of the 23 DHHC proteins. Interestingly, CSP palmitoylation was markedly enhanced by DHHC3, DHHC7, DHHC15 and DHHC17 ( Figure 1B ). To ensure that the observed enhancement of CSP palmitoylation was directly related to DHHC protein expression, we examined the effects of increasing amounts of DHHC3 plasmid (whilst maintaining the total amount of transfected DNA) on palmitoylation of co-transfected EGFP-CSP. Figure 1C clearly shows that increased palmitoylation of CSP was directly related to expression levels of DHHC3. Note that some of the DHHC proteins were poorly expressed in HEK293 cells ( Figure 1D ), and thus the identification of 4 enzymes that palmitoylate CSP may be an underestimate.
However, many non-active DHHC proteins were expressed at similar or higher levels than DHHC3/7/15/17, confirming the specificity of the results. The identification of DHHC17 as an enzyme that palmitoylates mammalian CSP agrees well with recent analyses of Drosophila mutants (26, 27) . Previous work has reported co-localisation of DHHC3/7/15/17 with Golgi markers (13, 15, 35) and we confirmed co-localisation of these proteins with the cis/medial Golgi protein giantin in HEK-293 cells ( Figure 2 ). We also compared the distribution of the DHHC proteins with the ER-Golgi intermediate compartment protein ERGIC-53 (supplementary Figure S1 ). The ERGIC-53 signal was present in puncta throughout the cytosol with some enrichment in a region of the cell that was closely positioned although clearly distinct from the DHHC proteins. Thus, DHHC3/7/15/17 are mainly localised to the Golgi with only minimal overlap with the ER-Golgi intermediate compartment.
Several other DHHC proteins are also localised to the Golgi in HEK293 cells (data not shown and see reference (35)), and hence there is clearly substrate specificity within this Golgi subset of DHHC proteins. It will be interesting to determine the factors that regulate this substrate specificity.
DHHC Proteins Regulate Stable Membrane
Binding of CSP In PC12 cells, palmitoylated EGFP-CSP associates tightly with membranes ( Figure 3A ) (24) . We recently proposed that the hydrophobic cysteine-rich domain of CSP facilitates membrane anchoring prior to palmitoylation (24) . However, it is not clear whether this interaction is stable or weak/transient. The inefficient palmitoylation of EGFP-CSP in HEK293 cells allowed us to address this question. Indeed, despite the large fraction of unpalmitoylated EGFP-CSP in HEK293 cells, we did not detect any significant quantity of this unpalmitoylated protein in the membrane fraction ( Figure 3A ). This suggests that the cysteine-rich domain is not able to mediate stable membrane binding of full-length CSP in the absence of palmitoylation. Confocal imaging also revealed a dispersed, mainly cytosolic localisation of EGFP-CSP in HEK293 cells ( Figure 3B ). As specific DHHC proteins enhance CSP palmitoylation in HEK293 cells ( Figure 1B) , we therefore tested whether these enzymes were sufficient to catalyse stable membrane binding of CSP. Thus, HEK293 cells were co-transfected with EGFP-CSP and each of the 23 HA-tagged DHHC constructs and subsequently fractionated into cytosol and membrane fractions. As with the analyses of whole cell lysates, DHHC3, DHHC7, DHHC15 and DHHC17 specifically and significantly enhanced palmitoylation of EGFP-CSP and the palmitoylated protein was exclusively present in the membrane fraction ( Figure 3C and 3D) . Thus, expression of these specific DHHC proteins is sufficient to catalyse the extensive palmitoylation of CSP and to promote its stable membrane attachment. Interestingly, DHHC11-coexpression consistently reduced CSP membrane interaction. To ensure that the effects observed upon co-expression of specific DHHC proteins were directly related to the enzymatic activity of the proteins, we introduced inactivating point mutations into the DHHC domains of both DHHC3 and DHHC7 as previously described (10, 11, (13) (14) (15) . Despite being expressed at similar levels as the wild-type DHHC3/7 proteins, these inactive mutants had n o s t i m u l a t o r y e f f e c t o n C S P palmitoylation/membrane binding in HEK293 cells, and indeed both mutants inhibited CSP palmitoylation (significant only for DHHC3) ( Figure 3E ). As a further control, we confirmed that the prepared cytosol and membrane fractions contained the entire pool of transfected EGFP-CSP with no protein remaining in the insoluble cell fraction ( Figure 3F ). We next examined whether the DHHC enzymes that palmitoylate CSP in transfected HEK293 cells are expressed in PC12 cells. For this, RT-PCR was performed on RNA purified from PC12 cells. Figure 3G shows that amplification products of the expected size were obtained from PCR reactions using DHHC3, DHHC7 or DHHC17 primers. In contrast we did not detect a signal for DHHC15 by RT-PCR ( Figure 3G ). However, when an aliquot of the DHHC15 RT-PCR was subjected to a second round of PCR a faint band was now visible (data not shown). The results of the PCR amplifications were obtained using 2 independent RNA samples.
Correlation Between Enhanced Membrane Affinity of CSP Mutants, Palmitoylation and Intracellular Localisation
We previously identified two unpalmitoylated CSP mutants that were localised predominantly by guest on July 11, 2017 http://www.jbc.org/ Downloaded from to the ER in PC12 cells; these mutants either contained a truncation of the C-terminus immediately after the cysteine-rich domain (CSP136) or replacement of 4 cysteines in the cysteine-string domain with leucine residues (CSP4CL) (24) . Based upon the results of current experiments showing localisation of CSP-palmitoylating DHHC proteins to Golgi membranes, we reasoned that the lack of palmitoylation of CSP136 and CSP4CL might be related to perturbations of initial membrane interactions, leading to accumulation of these mutants on 'inappropriate' membranes. It is not easy to determine if CSP136 and CSP4CL have an altered membrane affinity relative to wildtype CSP in PC12 cells due to efficient palmitoylation of the wild-type protein in this cell type (24) . Thus, we analysed membrane binding in HEK293 cells, which express only limited amounts of DHHC protein(s) active against CSP. This analysis clearly revealed that both CSP136 and CSP4CL associated more tightly with membranes than wild-type CSP ( Figure 4A ). Comparing the intracellular localisations of the two mutants with HA-DHHC3 in HEK293 cells highlighted a clear physical separation of the CSP mutants from the Golgi-localised DHHC protein ( Figure 4B) ; as in PC12 cells, both CSP mutants exhibited an ERlike distribution, similar to the ER resident protein calreticulin ( Figure 4B, bottom panel) . Thus, CSP mutants that enhance membrane affinity promote association with 'inappropriate' cell membranes, offering one explanation for the finding that these mutants are not efficiently palmitoylated in PC12 cells (24) . In support of this idea, neither CSP136 nor CSP4CL were palmitoylated when co-transfected with DHHC3 or DHHC7 in HEK293 cells (see Figure 8A) . Interestingly, the level of membrane binding of CSP truncation mutants expressed in HEK293 cells decreased significantly as amino acids were added to the C-terminus of the cysteine-string domain, and the presence of K137-P138-K139 in the CSP139 mutant weakened membrane binding significantly ( Figure 4C and 4D) . Strikingly, this loss of membrane binding correlated near perfectly with the appearance of a palmitoylated fraction of EGFP-CSP ( Figure  4C , asterisk) (24) , further highlighting the inverse correlation between membrane affinity of CSP mutants and palmitoylation.
Membrane Binding and Palmitoylation of CSP are Insensitive to BFA
The results presented thus far are consistent with the notion that wild-type CSP likely has a weak membrane affinity (mediated by the cysteinestring domain), which is enhanced either by Cterminal truncation or by the introduction of more hydrophobic amino acids. To determine whether wild-type CSP has a specific affinity for Golgi membranes or a more general membrane affinity, we examined the effects of brefeldin A (BFA) on membrane binding and palmitoylation. BFA inhibits the function of ARF1 (36,37), a protein essential for vesicle budding from the ER. BFA treatment thus blocks ER-to-Golgi transport and promotes a loss of Golgi integrity and fusion of Golgi membranes with the ER (37) . In a first set of experiments, HEK293 cells were transfected with EGFP-CSP with or without DHHC3 or DHHC7. Four hours posttransfection, the cells were incubated in the presence or absence of 30 µg/ml BFA for a further four hours and subsequently fractionated. In this experimental set-up, BFA will prevent the trafficking of co-transfected DHHC3 and DHHC7 from the ER. Figures 5A and 5B shows that BFA treatment did not inhibit membrane binding or palmitoylation of EGFP-CSP either in the absence or presence of DHHC cotransfection. This result implies that CSP palmitoylation does not require a specific intracellular localisation of partner DHHC proteins, but only sufficient cellular expression levels. These results are thus consistent with the notion that CSP has a general membrane affinity rather than recognising specific features inherent to intact Golgi membranes. As BFA had no effect on membrane binding or palmitoylation of EGFP-CSP, we checked whether this drug was having the expected effects on Golgi proteins. BFA was thus added to cells transfected with HA-DHHC3; this treatment clearly promoted the redistribution of HA-DHHC3 from a tight ribbon-like morphology to a dispersed localisation ( Figure  5C ). Staining was visible around the nucleus, consistent with at least partial redistribution to the ER. The presence of cycloheximide in these experiments ensures that the observed localisation of DHHC3 represents a redistribution of the protein rather than trapping of newly synthesised protein. Thus, BFA has the expected effects on Golgi-localised DHHC proteins in HEK293 cells. To extend these observations and to determine whether CSP membrane association and palmitoylation is also BFA-resistant in a cell type that expresses endogenous CSP, we examined membrane binding/palmitoylation of EGFP-CSP in PC12 cells. Due to lower transfection efficiencies in this cell type, we were unable to detect protein expression by immunoblotting 8 hours post-transfection. Thus, we performed [
35 S] cysteine/methionine pulsechase experiments to follow membrane binding and palmitoylation specifically of newly synthesised EGFP-CSP. As a first step we examined the time-course of membrane association and palmitoylation by labelling the cells for 15 mins and then removing the radiolabel and fractionating the cells after an additional 15-60 mins ( Figure 6A ). Two significant observations were made from this experiment: (i) there was a time-dependent appearance of palmitoylated CSP on membranes (asterisk); (ii) although unpalmitoylated CSP (arrowhead) was clearly associated with membranes, the level of membrane association of unpalmitoylated CSP was relatively constant over time. This would be expected if a protein with a weak membrane affinity was transiently associating to cell membranes. Having established that CSP palmitoylation was readily detectable following a 60 min 'chase' period, we next examined the effects of BFA treatment on membrane binding and palmitoylation of newly synthesised EGFP-CSP in PC12 cells. Thus, ~40 hours post-transfection, cells were incubated with or without BFA for 15 min. The cells were then incubated in radiolabel for 15 min, washed and incubated for a further 60 min in the presence/absence of BFA. CSP palmitoylation in this assay is dependent upon endogenous DHHC proteins; BFA treatment will promote redistribution of Golgi DHHC proteins to a fused ER-Golgi compartment. As a control, we examined the effects of BFA treatment in this assay on the membrane association of EGFP-SNAP25; as previously described (38) the membrane attachment of this palmitoylated protein was significantly inhibited by BFA treatment ( Figure 6B ). In contrast, BFA had no significant effect on either palmitoylation or membrane association of radiolabelled EGFP-CSP ( Figure 6C and 6D) . Thus, in both HEK293 cells and PC12 cells, membrane binding and palmitoylation of EGFP-CSP is independent of Golgi integrity or intracellular distribution of DHHC proteins. These results support the notion that CSP has a general (and weak) membrane affinity and that stable membrane attachment requires only sufficient cellular expression of appropriate DHHC proteins.
Brefeldin A Treatment Promotes Palmitoylation of CSP4CL but not CSP136
Having found that CSP-palmitoylating DHHC proteins retain activity after BFA treatment, we reasoned that BFA-mediated redistribution of Golgi-localised DHHC proteins to the ER might facilitate palmitoylation of the ER-localised CSP mutants. These experiments would thus allow us to determine whether CSP4CL and CSP136 are unpalmitoylated because they are present on distinct membranes to their partner DHHC proteins, or alternatively whether structural changes in the mutant proteins prevent their palmitoylation. Thus, we examined the effects of BFA treatment on palmitoylation of CSP136 and CSP4CL in PC12 cells. We did not detect any effect of BFA treatment on the palmitoylation status of either wild-type CSP or CSP136 ( Figure 7A ). Intriguingly though, we observed a robust palmitoylation of CSP4CL after as little as 1 hour BFA treatment ( Figure 7A ). This observation suggests that BFA-induced mixing of ER and Golgi membranes allows access of Golgi DHHC proteins to CSP4CL, facilitating the palmitoylation of this mutant. The effects of BFA were likely attributable to redistribution of Golgi enzymes to the ER rather than 'trapping' of newly synthesised DHHC proteins in the ER, as treatment with cycloheximide to block protein synthesis did not affect BFA-induced palmitoylation of CSP4CL ( Figure 7B ). As an additional control, we also examined the effects o f nocodazole on the BFA-induced palmitoylation of CSP4CL; nocodazole prevents the assembly of microtubules, which are required for BFA-induced fusion of ER and Golgi membranes (39) . As can be seen in Figure  7C the presence of nocodazole blocked BFAinduced palmitoylation of CSP4CL, implying that ER-Golgi fusion is essential for the effects observed. Overall, these results in PC12 cells are particularly relevant as they strongly support the conclusion that DHHC proteins active against CSP are localised predominantly to the Golgi. Furthermore, they support the notion that lack of CSP4CL palmitoylation results from a physical separation of this mutant from these Golgi localised DHHC proteins. Note that these experiments were performed 4 0 hours post-transfection and thus following extensive intracellular accumulation of by guest on July 11, 2017 http://www.jbc.org/ Downloaded from unpalmitoylated CSP4CL, emphasising the efficiency of BFA-induced palmitoylation; roughly 40% of the intracellular CSP4CL was palmitoylated within 1 hour of BFA treatment ( Figure 7 ). In comparison, only around 20% of wild-type CSP produced during a 15 min labelling period was palmitoylated within a similar time-frame ( Figure 6 ). These results therefore suggest that, following BFA-induced re-localisation of Golgi enzymes to the ER, palmitoylation of CSP4CL is more efficient than palmitoylation of wild-type CSP. The most likely explanation for these findings is that whereas palmitoylation of CSP is limited by its weak membrane affinity, the tighter membrane binding of CSP4CL ensures a faster rate of palmitoylation when Golgi enzymes are relocalised to the ER. HEK293 cells contain sufficient DHHC proteins to palmitoylate only a small pool of wild-type CSP (Figures 1,3 and 5) . We reasoned that if the extent of CSP palmitoylation is regulated by (i) the transient nature of membrane association of unpalmitoylated CSP, and (ii) the expression levels of DHHC proteins, then the enhanced membrane affinity of CSP4CL should facilitate a more efficient palmitoylation of this mutant in BFA-treated HEK293 cells than observed for wild-type CSP. To test this idea, we performed BFA experiments in HEK293 cells transfected with CSP4CL and CSP136 (as described for Figure 5 ). As predicted BFA treatment of HEK293 cells promoted an ~ 7-fold increase in the extent of CSP4CL palmitoylation, with around 70% of the protein palmitoylated following BFA treatment (Figure 8 ). This was in contrast to the almost complete lack of CSP4CL palmitoylation when transfected either in the absence or presence of DHHC3/7 but without BFA-induced mixing of ER/Golgi membranes ( Figure 8A ). Thus, when localised to the same intracellular compartment as partner DHHC proteins, the enhanced membrane affinity of CSP4CL facilitates a faster rate of palmitoylation. As in PC12 cells, CSP136 was not palmitoylated in BFA-treated HEK293 cells, either in the absence or presence of DHHC3/7 co-expression ( Figure 8A ). The inability of BFA treatment to promote palmitoylation of CSP136 suggests that residues in the C-terminus (such as K137-P138-K139) are important for palmitoylation. Indeed, we previously reported that a CSP(K137A) mutant was not efficiently palmitoylated in PC12 cells (24) . The CSP136 mutant might also adopt a membrane orientation that indirectly prevents palmitoylation. For example, it is possible that the lack of a significant amount of charged residues at the C-terminal end of CSP136 results in the protein 'slipping' into the membrane interior, thus preventing interaction with DHHC proteins.
CSP4CL Does not Noticeably Redistribute Following BFA Washout
Palmitoylation plays an important role in the trafficking of many proteins (3). To determine if CSP palmitoylation is always coupled to forward transport in the secretory pathway, we performed BFA washout experiments (37) to analyse whether palmitoylated CSP4CL protein is able to traffic from the ER. As a control for a Golgi protein, we transfected cells in parallel with EGFP-tagged DHHC-17. Cells were either treated with BFA for 2 hours in the presence of c y c l o h e x i m i d e , o r t r e a t e d w i t h BFA/cycloheximide, washed 5 times in fresh media containing cycloheximide but without BFA, and allowed to recover for 4 hours. Cells were fixed and examined by confocal imaging. As shown in Figure 9A , DHHC17 showed the expected distributions: Golgi in control cells, dispersed after BFA treatment and Golgi following BFA washout. To quantify these changes we examined DHHC17 distribution and scored the cells for either Golgi localisation or dispersed (ER) distribution ( Figure 9B ). Interestingly, and in contrast to DHHC17, we did not detect any changes in the distribution of CSP4CL following BFA washout ( Figure 9A ). This finding suggests that palmitoylation is not sufficient to direct exit of CSP4CL from the ER. We speculate that the amino acid sequence/structure of palmitoylated CSP facilitates the movement into budding vesicle at the Golgi but not at the ER. Thus, the specific intracellular compartment at which CSP is palmitoylated, and hence stably anchored to, is likely to play a major role in determining targeting specificity.
Concluding Remarks
The identification of DHHC3, -7, -15 and -17 as enzymes that can palmitoylate CSP and lead to its stable membrane binding suggests that there may be some redundancy in palmitoylation of DHHC substrates. Alternatively, different DHHC isoforms may palmitoylate CSP in distinct cell types and tissues. All the enzymes identified as CSP PATs display some degree of substrate specificity. DHHC17 did not palmitoylate PSD-95, GAP-43, Gα or the γ2 subunit of GABA A (14, 40) . Similarly, DHHC15 was inactive against Lck, H-ras and Gα, and was only marginally active against the γ2 subunit of GABA A (14, 40) . DHHC7 did not enhance palmitoylation of Lck or H-ras, whereas DHHC3 was not active against Lck (14) . Furthermore, many of the DHHC proteins that tested negative in our assay have previously been shown to palmitoylate specific substrates (see e.g. (14,41) . Thus, there appears to be a good degree of specificity exhibited by the DHHC proteins that palmitoylate CSP. At present we do not know how CSP/DHHC specificity is regulated, but some possibilities include: (i) specific structural features of the DHHC region and/or other domains of DHHC3/7/15/17 regulating interaction with CSP; (ii) the association of these DHHC proteins with specific sub-domains of the Golgi, which facilitates interaction with CSP; and (iii) specific co-factors that regulate the CSP/DHHC interaction (16) . Based upon the work presented, we propose a model for CSP membrane binding and palmitoylation, whereby CSP utilises a weak membrane affinity to bind transiently to cell membranes and 'sample' them for DHHC content. Upon association with Golgi membranes, CSP is recognised by DHHC3/7/15/17, which catalyse the palmitoylation and stable membrane anchoring of CSP, facilitating forward transport ( Figure  10 ). At the heart of this model is the proposed transient membrane association of CSP. Although we do not have direct data to show reversible association of CSP with membranes, the following points are consistent with this idea: (i) specific mutations around or within the cysteine-string domain lead to stable membrane binding, consistent with the wild-type protein having an underlying membrane affinity; (ii) in silico analysis identified a region in CSP including the cysteine-string domain having a propensity to move to the membrane interface but not traverse the bilayer, and experiments in vitro showed an association of recombinant CSP with isolated cellular membranes (25); (iii) experiments comparing the extent of palmitoylation of wild-type CSP and CSP4CL following BFA treatment (Figures 7 and 8) suggest that palmitoylation of wild-type CSP is rate-limited by membrane affinity. This observation is consistent with unpalmitoylated CSP having a slow membrane binding step, or a rapid dissociation from membranes; (iv) pulsechase experiments in PC12 cells reveal a timedependent increase in palmitoylated CSP on membranes but very little change in the extent of unpalmitoylated CSP in the membrane fraction. These observations would be predicted if CSP was rapidly associating/dissociating from membranes and required palmitoylation for stable membrane binding (as we propose). Analyses of CSP truncation mutants highlighted a key role for a lysine-proline-lysine motif immediately downstream of the membranebinding domain (Figure 4 ). This motif weakens membrane affinity of truncation mutants and at the same time facilitates efficient palmitoylation. Interestingly, mutation of this domain in fulllength CSP did not lead to accumulation of unpalmitoylated CSP on membranes (supplementary Figure S2) , implying that the intact C-terminus of full-length CSP (which is highly charged) can regulate membrane association in the absence of the KPK motif. Nevertheless, this amino acid triplet is clearly important for palmitoylation of full-length CSP, perhaps regulating the affinity of DHHC interaction (see supplementary Figure S2 and reference (24)). One possibility that we wanted to exclude was that the loss of tight membrane binding of CSP136 following addition of KPK (Figure 4) did not simply occur due to the addition of any amino acids downstream of the cysteine-string. To test this, we introduced a K137A mutation into a CSP143 mutant (Supplementary Figure S2) . Replacement of K137 in this mutant promoted a large increase in membrane binding and similarly a decreased palmitoylation. Thus, we can conclude: (i) the KPK motif is essential for palmitoylation of CSP; (ii) this motif affects the membrane interaction of CSP (mutants); and (iii) residues between amino acids 144-198 are also important for weakening membrane affinity of CSP and are sufficient in this regard following removal of the KPK motif. The role of palmitoylation in regulating protein sorting is an emerging area of cell biology (3). Although palmitoylation of CSP is essential for sorting of CSP, it is not clear whether palmitoylation plays an active role in this process (for example by driving association of CSP with budding vesicles) or an indirect role (by promoting stable membrane attachment and thus allowing other domains of CSP to facilitate sorting). Whatever the mechanism, our by guest on July 11, 2017 http://www.jbc.org/ Downloaded from experiments examining CSP4CL localisation following BFA washout ( Figure 9 ) suggest that palmitoylation of CSP can be uncoupled from forward transport in the secretory pathway. It is formally possible that loss of specific palmitoylated cysteines in the CSP4CL mutant directly inhibits traffic from the ER (ie that CSP needs to be fully palmitoylated to traffic). This is unlikely given that we have previously shown that other CSP mutants lacking 3-4 cysteines (and hence palmitoylation sites) traffic similarly to wild-type protein (24) . Thus, we favour the view that forward traffic of palmitoylated CSP is linked to palmitoylation at a specific cell location (ie the Golgi) and that factors required for CSP sorting are not present at the ER following BFA washout. The results of this study are reminiscent of recent work studying palmitoylation and trafficking of H-and N-Ras (6,7). Farnesylation of these proteins provides a weak membrane affinity (42, 43) . This initial membrane interaction is weak and presumed to allow Ras to associate with any intracellular membrane. Because the Ras palmitoyl transferase, DHHC9, is localised to ER/Golgi membranes (16), palmitoylation only occurs on these membranes, probably allowing access of Ras to the secretory pathway and facilitating its forward transport to the plasma membrane (6, 7) . Our results suggest that membrane 'sampling' through transient membrane interactions is not restricted to lipidated (prenylated or myristoylated) proteins but may also occur via specialised protein domains, such as the cysteine-string domain of CSP.
We are very grateful to Rory Duncan and Colin Rickman (University of Edinburgh) for advice and help with confocal imaging analysis. EGFP-DHHC17 plasmid was provided by Alaa El-Husseini. 1-23) was determined by densitometry, and averaged data is presented (n=5). * denotes a p value of <0.03, whereas ** indicates a p value of <0.004 compared with CSP in the absence of DHHC co-expression. E) HEK293 cells were cotransfected with EGFP-CSP and wild-type HA-tagged DHHC3/DHHC7 or with the inactive DHHC mutants, DHHC3 (C157S)/DHHC7 (C160S). Cells were fractionated into cytosol (C) and membrane (M) fractions, and equal volumes were resolved by SDS-PAGE, transferred to nitrocellulose and probed with antibodies against GFP and HA. Representative blots are shown in the left panel. The Right panel shows the % membrane association +/-SEM of EGFP-CSP under the different transfection conditions determined by quantification of immunoblots (n=6). * denotes a p value of <0.03, ** indicates a p value of <0.003, and *** denotes a p value of <0.0006 compared with EGFP-CSP in the absence of DHHC expression F) HEK293 cells were co-transfected with EGFP-CSP and DHHC3, DHHC7, DHHC15 or DHHC17 and fractionated into cytosol (C) and membrane (M) fractions. The remaining insoluble (I) cell material was solubilised in SDS-dissociation buffer. Equal volumes of the recovered fractions were resolved by SDS-PAGE and transferred to nitrocellulose for immunoblotting analysis using anti-GFP. G) Primers recognising DHHC3, DHHC7, DHHC15 and DHHC17 were used in PCR reactions that contained purified plasmid DNA ('3', DHHC3 template; '7', DHHC7 template, '15', DHHC15 template; '17', DHHC17 template), no DNA (-) or cDNA (C). Position of selected standards (in kilobase pairs) is shown on the left. The predicted sizes of amplification products were: DHHC3, 903bp; DHHC7, 928bp; DHHC15, 716 bp; DHHC17, 1164bp. The position of molecular weight standards is shown on the left side of all panels; asterisks denote palmitoylated CSP and arrowheads indicate unpalmitoylated CSP. fractions, from which EGFP-SNAP25B was recovered by immunoprecipitation and subsequently analysed by immunoblotting with anti-GFP (GFP). Duplicate gels were developed using autoradiography ([ 35 S] ). The % membrane binding +/-SEM of EGFP-SNAP25 in the presence and absence of BFA was determined by densitometry of autoradiographs. *denotes a p value of <0.005 compared with EGFP-SNAP25 in the absence of BFA. C) Cells transfected with EGFP-CSP were treated as described for SNAP25. D) The % membrane binding +/-SEM of EGFP-CSP in the presence and absence of BFA was determined by densitometry of autoradiographs (left panel). The % palmitoylation of EGFP-CSP was determined as a percentage of the total membrane-bound pool (right panel). Arrowheads indicate unpalmitoylated CSP, whereas asterisks denote palmitoylated CSP. The position of molecular weight standards is shown on the left of all panels. Figure 7 . Effect of BFA on palmitoylation of CSP proteins in PC12 cells. A) PC12 cells transfected with EGFP-CSP, CSP136 or CSP4CL were treated with 30 µg/ml BFA for 1 hour or 4 hours or left untreated ('0'). The cells were then fractionated into cytosol (C) and membrane (M) fractions, and equal volumes of each fraction were separated by SDS-PAGE and transferred to nitrocellulose for immunoblotting analysis using anti-GFP. B) As panel (A) except shown only for EGFP-CSP4CL, which was treated with or without BFA in the presence of 10 µg/ml cycloheximide (CHX). Top panel shows a representative immunoblot, whereas bottom panel shows averaged data +/-SEM for % palmitoylation of membrane-bound CSP4CL (n=5). * denotes a p value of <0.02 and ** is p<0.003 compared to % palmitoylation in the absence of BFA treatment. C) Cells were incubated for 4 hours with or without 30 µg/ml BFA in the presence or absence of 10 µg/ml nocodazole as indicated. Noco+ indicates where nocodazole was added 2 hours before the addition of BFA, and maintained throughout BFA treatment. Cycloheximide (10 µ g/ml) was present in all samples. For all immunoblots shown, the position of molecular weight standards are shown on the left and unpalmitoylated and palmitoylated CSP bands are indicated by arrowheads and asterisks, respectively. shows averaged data for % palmitoylation +/-SEM of membrane bound CSP4CL (without co-expression of DHHCs) in the absence or presence of BFA treatment (n=7). * denotes a p value of <0.0000005. Position of molecular weight standards are shown on the left; arrowhead denotes unpalmitoylated CSP, whereas asterisk highlights palmitoylated CSP. Figure 9 . Intracellular localisation of EGFP-CSP4CL following BFA treatment and washout. PC12 cells transfected with EGFP-CSP4CL or EGFP-DHHC17 were either untreated (control), incubated in 30 µg/ml BFA and 10µg/ml cycloheximide for 2 hours ('+BFA'), or BFA/cycloheximide treated and then washed and incubated in the presence of cycloheximide for 4 hours ('BFA washout'). Cells were examined using a Zeiss LSM510 axiovert laser scanning confocal microscope. For clarity, a rough outline of the cell membrane (solid line) and nuclei (dashed line, n) is shown for EGFP-DHHC17-expressing cells that were untreated or subjected to BFA washout. Scale bars represent 10 µm. B) EGFP-DHHC17-expressing cells under all treatments were scored for a Golgi localisation or an ER (dispersed) localisation. The total number of cells counted was 61 for the control condition, 50 for BFA treatment and 74 for BFA washout. (1) . Upon binding to Golgi membranes, CSP is recognised and palmitoylated by its partner DHHC proteins (2) . Palmitoylation leads to stable membrane binding of CSP, and may facilitate forward transport. B) The enhanced membrane affinity of CSP136 and CSP4CL leads to tight binding to the most abundant cellular membranes, such as the ER, and physical separation from Golgi-localised DHHC proteins. C) BFA treatment induces the fusion of ER and Golgi membranes and puts CSP4CL and DHHC proteins on the same membrane compartment. This membrane mixing allows palmitoylation of CSP4CL but is not sufficient to allow transport out of the ER.
